INTRODUCTION
The Golgi complex modifies and sorts proteins and lipids in the secretory pathway (Farquhar and Palade, 1981; Mellman and Simons, 1992; Rothman and Orci, 1992) . Secreted proteins typically transit the mammalian Golgi complex in several minutes, whereas the resident Golgi proteins that function to modify these secretory molecules are localized to the Golgi for periods extending to several days. The mechanism that localizes resident Golgi proteins has been the subject tCorresponding author: Department of Biological Sciences, Car- negie Mellon University, Pittsburgh, PA 15213. of extensive investigation, but the theories derived from these studies remain controversial. One theory states that resident Golgi proteins form oligomers too large to enter transport vesicles and that these oligomers stay behind in the Golgi as secretory molecules travel forward (Nilsson et al., 1991; Swift and Machamer, 1991) . Oligomer-based retention can explain why overexpression of Golgi proteins leads to backup in the endoplasmic reticulum (ER) rather than mislocalization to post-Golgi compartments (Munro, 1991; Nilsson et al., 1991; Swift and Machamer, 1991) . Indeed, versions of a chimeric viral protein that are Golgi-localized are recovered in cell extracts as large SDS-resistant oligomers, whereas mutant versions that are not retained in the Golgi fail to form oligomers (Weisz et al., 1993) . Also, mislocalization of the medial Golgi enzyme N-acetylglucosaminyltransferase I to the ER caused ER accumulation of mannosidase II, another medial Golgi enzyme, suggesting that heterooligomers form in vivo and are important for targeting . On the other hand, large oligomers of Golgi proteins would be expected to have low mobilities in the membrane, and recent work indicated that several chimeric Golgi-localized proteins actually had very high mobilities (Cole et al., 1996) .
An alternative theory states that the length of the transmembrane segment excludes resident Golgi proteins from transport vesicles (Bretscher and Munro, 1993; Masibay et al., 1993) . It has been demonstrated in numerous studies that the transmembrane domains of resident Golgi proteins are required for proper localization (reviewed in Machamer, 1993; Nilsson et al., 1993) . Golgi-resident enzymes are mostly type II membrane proteins with membrane-spanning domains that are an average of five amino acids shorter than those of type II plasma membrane proteins (Bretscher and Munro, 1993; Masibay et al., 1993) . Increasing the length of the transmembrane segments led to the mislocalization of several Golgi proteins to the plasma membrane (Munro, 1991; Masibay et al., 1993) . How might transmembrane domain length exclude a protein from transport vesicles? One possibility is that a higher cholesterol content in the transport vesicle membrane makes this membrane too thick to accommodate a short transmembrane segment (Bretscher and Munro, 1993) . Nevertheless, under in vitro conditions, it has been shown that Golgi membrane proteins are in fact incorporated into Golgi-derived transport vesicles (Sonnichsen et al., 1996) .
In addition to these postulated retention mechanisms, retrieval plays a role in localizing proteins to the Golgi. Retrieval mechanisms are characterized in part by their saturability. Trans-Golgi network protein 38 kDa (TGN38) and furin are localized to the transGolgi network, but they cycle through post-Golgi compartments (Reaves et al., 1993; Wong and Hong, 1993) . Overexpression of either protein leads to increased accumulation in endosomes (Bos et al., 1993; Humphrey et al., 1993; Chapman and Munro, 1994; Reaves and Banting, 1994) . In contrast to the resident proteins of earlier Golgi compartments, TGN-localized proteins may have either a type I or a type II topology, and the cytoplasmic tails of these proteins are critical for their localization to the Golgi (Bos et al., 1993; Humphrey et al., 1993; Nothwehr et al., 1993; Wong and Hong, 1993) . As in other recycling pathways, the cytoplasmic tails of TGN-localized proteins are thought to contain signals that promote incorporation into recycling vesicles (Voorhees et al., 1995) . Thus, a general scheme emerges in which targeting of type II proteins to the Golgi stack involves retention, whereas targeting of TGN proteins involves retrieval (Machamer, 1993; . However, there is evidence that at least some type II proteins may cycle within the Golgi stack (Johnston et al., 1994; Hoe et al., 1995; Harris and Waters, 1996) . For example, Ochlp, a type II early Golgi protein from Saccharomyces cerevisiae, acquires late Golgi modifications with a half-time of 5 min, even though Ochlp has a half-time for residence in the Golgi of 60 min (Harris and Waters, 1996) . These data suggest that Ochlp is repeatedly retrieved from a late Golgi compartment.
Obviously, it is unlikely that a single process explains the targeting of all resident Golgi proteins. Different Golgi proteins probably use different localization mechanisms, and more than one mechanism may operate in the localization of a given protein. A comprehensive understanding of Golgi localization will require analysis of a diverse array of Golgi proteins. This article describes the sequence and biochemical characterization of GPP130 (Golgi phosphoprotein of 130 kDa), a type II protein that resides in the cis/ medial Golgi. On the basis of shared properties, including antibody cross-reactivity, GPP130 appears to be the human homologue of a rat Golgi-localized antigen known as Golgi integral membrane protein, cis (GIMPc). Despite its localization to the early Golgi, GIMPc acquires late Golgi modifications (Yuan et al., 1987) . Unlike other mammalian type II Golgi proteins, GPP130/GIMPc redistributes to post-Golgi compartments when the cells are treated with chloroquine, suggesting that GPP130/GIMPc is targeted to the early Golgi by a saturable pH-sensitive retrieval pathway.
MATERIALS AND METHODS Preparation of Monoclonal Antibodies
The mouse monoclonal antibody A1/118, an IgGl, was obtained by the hybridoma technique (Hauri et al., 1985) using PAI myeloma cells as the fusion partner. A membrane fraction enriched in ERGIC-53 was isolated from Vero cells (Schweizer et al., 1991) 
Immunofluorescence and Immunoelectron Microscopy
Immunofluorescence was performed as described previously (Linstedt and Hauri, 1993) except that the cells were grown on 12-mm circular glass coverslips and digital images were acquired in the program Photoshop (Adobe Systems, Mountain View, CA) using a fluorescence microscope (Nikon, Melville, NY) equipped with a Molecular Biology of the Cell Hamamatsu black-and-white cooled charge-coupled device camera (Hamamatsu Photonics K.K., Hamamatsu City, Japan). Antibody dilutions were as follows: Al /118 at 1:100, anti-giantin (Linstedt et al., 1995) at 1:1000, anti-galactosyltransferase (Berger et al., 1986) at 1:200, and anti-mannose-6-phosphate receptor at 1:500. Fixable fluorescein isothiocyanate (FITC)-dextran (Mr, 10,000, Molecular Probes, Eugene, OR) was added to DMEM at 1 mg/ml and the cells were cultured for 1 h and then fixed for 12 h. Antibody uptake was performed by incubation of cells with 1 ,ug/ml A1/118 or antigiantin for 3 h in DMEM. The cells were then fixed and processed as indicated above except that primary antibodies were omitted. For immunoelectron microscopy, Vero cells were fixed with 2% formaldehyde containing 0.01% glutaraldehyde and processed as described previously (Reggio et al., 1983) . Altematively, COS-7 cells cultured on 35-mm plates were fixed with 3% paraformaldehyde for 24 h, washed twice with phosphate-buffered saline (PBS) and twice with PBS containing 20 mM glycine, and then permeabilized for 20 min with PBS-glycine containing 0.1% saponin. Antibody incubations were in 1 ml of PBS-saponin for 1 h and were followed by five washes with PBS-saponin. Al/118 and horseradish peroxidase-labeled goat anti-mouse (Cappel, West Chester, PA) were used at a 1:100 dilution. Controls omitted the primary antibody. The samples were further processed as follows: three PBS washes, 30 min in 1% OS04 buffered with PBS, three water washes, dehydration in an ethanol series (50%, 70%, 80%, 90%, and 100%), infiltration in a 1:1 mixture of 100% ethanol:Epon-araldite for 1 h, 100% Epon-araldite for 18 h in a desiccator, 100% Epon-araldite for 48 h in a desiccator, 35°C for 48 h, 50°C for 24 h, 60°C for 12 h. Pieces of the polymerized Epon-araldite disk were sectioned and viewed on a Hitachi 7100 transmission electron microscope at 50 keV. Digital images were recorded with an AMT Advantage 10 image acquisition system (AMT, Danvers, MA), using a Kodak Megaplus 1.61 charge-coupled device camera and National Institutes of Health Image acquisition software.
Metabolic Labeling and Immunoprecipitation
In vivo phosphorylation was as follows. COS-7 cells were grown to near confluency in a six-well dish in DMEM containing 10% calf serum. The cells were washed and then incubated for 30 min with phosphate-free DMEM. Labeling was carried out for 3 h in 0.5 ml of phosphate-free DMEM containing 0.25 mCi/ml [32Plorthophos-phate (Dupont NEN, Wilmington, DE). Cell lysates were prepared by addition of RIPA buffer containing inhibitors (1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 20 mM triethanolamine pH 7.5, 50 mM NaF, 0.2 mM Na3VO4, 1 ,uM microcystin, 1 ,ug/ml pepstatin, 1 ,ug/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride). Methionine labeling was as follows. COS-7 cells in a six-well dish were washed and incubated for 30 min with methionine-and cysteine-free DMEM. Labeling was carried out for 30 min in 0.5 ml of the same medium containing 0.1 mCi/ml 355-labeling mixture (Dupont NEN). Chase incubations were carried out for the indicated times in normal growth medium. Lysates were prepared as described above except that phosphatase inhibitors were not present. Immunoprecipitation of the lysates was as follows. After incubation for 30 min on ice, the lysate was centrifuged for 15 min in a microcentrifuge at 4°C, and the resulting supernatant was precleared and then rotated for 90 min at 4°C with 12 ,ul of Al /118-coated protein A-Sepharose (Pharmacia, Piscataway, NJ) or control beads. The Sepharose beads were collected and washed five times with 1 ml of RIPA buffer, boiled in sample buffer, and analyzed by SDS-PAGE (7% gels). Each 12 jil of protein A-Sepharose were coated by sequential incubations with 2 ,ul of rabbit antimouse IgG (Cappel) and 10 yl of Al/118. Control beads were incubated only with the rabbit anti-mouse IgG.
Subcellular Fractionation
Gradient fractionation was exactly as described (Linstedt et al., 1995) . HepG2 cells grown to confluence on three 15-cm plates were homogenized by 10 passages through a ball-bearing homogenizer with a clearance of 20 p.m in 3 ml of 120 mM NaCl, 5 mM KCI, and 25 mM NaHCO3 (pH 7.4) containing protease inhibitors. After centrifugation at 750 rpm for 10 min in an SS-34 rotor (Sorvall, Newtown, CT), the resulting postnuclear supernatant was applied to the top of a 12-ml linear Nycodenz gradient [13-29% (wt/vol) with a 1-ml 35% cushion; all solutions contained 10 mM triethanolamine, pH 7.4, 1 mM EDTA, and protease inhibitors]. After centrifugation at 25,500 rpm for 3 h in an TST-28.17 rotor (Kontron, Zurich, Switzerland) , the gradients were fractionated from the bottom, and each fraction was assayed for density, content of total protein, glucose 6-phosphatase, GalNAc transferase, and galactosyltransferase. The amount of GPP130 was determined by immunoblotting with Al /118 used at a 1:200 dilution. The Fl membrane fraction used in protease protection and extraction experiments was prepared as follows. HeLa cells grown to confluency were rinsed twice with ice-cold PBS, scraped into PBS, and collected by centrifugation. The pellet was resuspended and centrifuged in homogenization buffer (250 mM sucrose, 1 mM EDTA, 10 mM triethanolamine, pH 7.4, and protease inhibitors). The washed pellet was resuspended and homogenized in homogenization buffer (1 ml/10-cm plate) by 20 passages through a 25-gauge needle. The postnuclear supernatant, obtained by centrifugation of the homogenate at 1000 x g for 5 min, was adjusted to 50% sucrose (6-ml volume), and placed in the bottom of a centrifuge tube. Then, 45% (4 ml) and 10% (1.5 ml) sucrose steps were carefully overlayed. The resulting step gradient was centrifuged for 3 h at 30,000 rpm in a Kontron 41.14 swinging bucket rotor. The Fl fraction was collected from the 45%/10% interface with a pipette.
Cloning and Transfection
A unizap human intestinal cDNA library (Stratagene, La Jolla, CA) was first screened with Al/118 as described for immunoscreening (Ausubel et al., 1995) . Screening of 2.7 x 105 plaques yielded two positive clones that were plaque-purified, excised as inserts in Bluescript (Stratagene), and analyzed by restriction mapping and sequencing. The positive plaques were found to be derived from the same gene. A 1.1-kb XbaI fragment derived from the 5' end of one of the clones was then used as a probe to rescreen the library as described for cDNA screening (Ausubel et al., 1995) . This resulted in the isolation of a 4.0-kb clone that was sequenced by using exonuclease III nested deletions. By Northern blot analysis, the cDNA clone was lacking approximately 0.5 kb. A 5'-rapid amplification of cDNA ends kit (Life Technologies, Gaithersburg, MD) was used to isolate DNA encompassing the remaining 0.5 kb. Shared restriction sites were then used to piece together the entire open reading frame, which was then cloned into the EcoRI site of the expression vector pECE. The COS transfection protocol was as follows. COS-7 cells grown overnight to 75% confluence on a 60-mm plate were rinsed twice with PBS, incubated with 0.3 ml of PBS containing 2 ,ug of DNA and 10 p.g/ml DEAE for 30 min at 37°C, and then incubated with 2 ml of DMEM containing 10% NuSerum (Life Technologies) and 10 mM chloroquine for 3.5 h. This was followed by a 2-min incubation with DMEM containing 10% dimethyl sulfoxide and an overnight incubation in normal growth medium. The next day the cells were passaged onto plates or coverslips in preparation for analysis on the following day. CHO and HeLa, I x 106 cells in 0.1 ml of PBS, were transfected by electroporation in 0.4-cm cuvettes with a Gene Pulser (Bio-Rad, Richmond, CA) set at 0.3 kV and 250 ,uF. For transfection of HeLa TetON (Clontech, Palo Alto, CA) the cDNA was cloned into the pTRE vector (Clontech). Doxycycline (Sigma, St. Louis, MO) at 0.001 mg/ml was used for induction. (Schweizer et al., 1991) . Indirect immunofluorescence analysis of COS cells indicated that Al/118 recognized a Golgi-localized epitope ( Figure 1A ). This pattern was indistinguishable from the pattern of the Golgi protein giantin in the same cells ( Figure 1B Figure 1B ). The electron-dense reaction product accumulated within the Golgi lumen, suggesting that the antibody bound to a lumenal epitope. Staining was asymmetrically distributed on one side of a stack in Vero ( Figure 1B ), COS-7, and HeLa cells.
To determine whether the antigen is localized on the cis or trans side of the stack, we used a gradient fractionation protocol that separates the cis-Golgi marker GalNAc transferase from the trans-Golgi marker galactosyltransferase (Linstedt et al., 1995 To determine whether GPP130 is an integral component of Golgi membranes, we extracted isolated vesicles with 0.1 M sodium carbonate at pH 11.5. The membranes were also treated with low salt buffer or detergent-containing buffer. As expected for an integral membrane protein, the 130-kDa antigen remained membrane-associated after extraction unless detergent was added ( Figure 3A ). The protein was also not extracted by either 1 M NaCl or 5 M urea. Protease protection was used to determine the topology of GPP130 in the membrane. Isolated vesicles were treated with trypsin or proteinase K in the presence or absence of a membrane-solubilizing detergent. Reactivity of A1/118 with the 130-kDa antigen was protected from protease digestion in the absence of detergent but was completely lost in the presence of detergent ( Figure 3B ). This result indicates that the antigenic epitope and most or all of the GPP130 molecule resides in the Golgi lumen. GPP130 exhibited a Vol. 8, June 1997 a 'k Op slow increase in apparent molecular weight when cells were pulse labeled for 15 min and chased for 3 h, suggesting that it became glycosylated. Indeed the apparent molecular weight increase was prevented by tunicamycin treatment during the pulse and chase and was reversed by treatment with endoglycosidase F. Furthermore, purified GPP130 became labeled with biotinhydrazide, a reagent reactive with carbohydrate side chains. Immunoblotting and immunoprecipitation experiments indicated that migration of GPP130 during SDS-PAGE varied depending on which cell type was analyzed. For example, the Caco-2 antigen appeared as a doublet ( Figure 3A) , whereas the Vero antigen appeared as a single band ( Figure 3B ). This behavior may reflect differences in glycosylation and/or phosphorylation between different cell types.
Chloroquine Treatment Reversibly Alters the Intracellular Distribution of GPP130 TGN38, furin, and mannose-6-phosphate receptor continually recycle between the TGN and the cell surface (Griffiths et al., 1988; Reaves et al., 1993; Wong and Hong, 1993; Molloy et al., 1994) . Treatment of cells with weak bases such as chloroquine, which block the acidification of lumenal compartments, prevents the return of TGN proteins to the Golgi by blocking transport out of the late endosome (Brown et al., 1986; Chapman and Munro, 1994) . Chloroquine treatment also causes a dramatic enlargement of endosomal vesicles, resulting in a "Swiss cheese" appearance of the cytoplasm. Therefore, chloroquine treatment results in a redistribution of TGN proteins from the Golgi to dilated endosomes. In contrast, type II Golgi proteins such as N-acetylglucosaminyltransferase I, mannosidase II, sialyltransferase, and galactosyltransferase remain associated with the Golgi stack in chloroquinetreated cells (Berger et al., 1993; Chapman and Munro, 1994) . Because the behavior of these various proteins in response to chloroquine treatment is probably related to their targeting mechanisms, we examined the distribution of GPP130, giantin, and mannose-6-phosphate receptor in COS-7 cells treated with 0.1 mM chloroquine for 3 h. In untreated cells the giantin and GPP130 staining patterns were coincident (Figure 4, A  and B) . Surprisingly, chloroquine treatment led to the accumulation of GPP130 in dilated peripheral vesicles, but giantin staining remained in a characteristic perinuclear pattern (Figure 4 , C and D). The slight compaction of the giantin pattern has been observed for other Golgi proteins after chloroquine treatment (Chapman and Munro, 1994) Figure 4 , E and F). Three hours after chloroquine washout, GPP130 had recovered its Golgi localization (Figure 4 , G and H). However, both GPP130 and mannose-6 phosphate receptor still exhibited some staining in peripheral vesicles after washout. The contribution of newly synthesized GPP130 to the Golgi staining after washout was negligible because cycloheximide had no discernible effect. The dramatic relocalization of GPP130 to dilated vesicles indicated that, in contrast to previously characterized early Golgi proteins, GPP130 targeting requires acidification of lumenal compartments.
GPP130 Is a Type II Membrane Protein with an Unusually Acidic Lumenal Domain Expression screening of a human epithelial cDNA library with the Al/118 antibody resulted in the isolation of several overlapping clones. Subsequent cDNA screening identified a 4.0-kb cDNA that contained a poly(A) addition site at its 3' end and a large open reading frame at its 5' end. Northern blotting indicated that the corresponding HeLa mRNA was 4.5 kb. 5' rapid amplification of cDNA ends (Frohman et al., 1988 ) produced a PCR fragment containing an additional 0.5 kb of N-terminal coding sequence, flanked by a start codon with surrounding nucleotides that match the derived consensus for translational initiation (Kozak, 1996) . The DNA sequence encompassing the open reading frame and the predicted protein sequence are presented in Figure 5 . Surprisingly, the calculated molecular weight for GPP130 of 81,880 is substantially smaller than the apparent molecular weight derived from SDS-PAGE migration. Several observations indicate that this discrepancy is due to inherent properties of the GPP130 polypeptide rather than to posttranslational modifications such as glycosylation: tunicamycin treatment only slightly altered the migration of GPP130 on SDS-PAGE, a coupled in vitro transcription/translation reaction programmed with the GPP130 cDNA and performed in the absence of membranes produced a protein migrating at approxi- 
13 80 461 1861 621 (Brendel et al., 1992) . The distribution of glutamic acid ( Figure 6C ) and aspartic acid ( Figure 6D ) demonstrates that the C-terminal region of GPP130 contains a particularly large number of acidic residues. The GPP130 sequence contains a single predicted transmembrane domain of 20 amino acids (residues 13-32) near the N terminus (underlined in Figure 5 ). The output of the TMPred program (Hofmann and Stoffel, 1993) is shown in Figure 6A . Several other algorithms yielded a similar prediction. The large CMolecular Biology of the Cell terminal domain is hydrophilic and, based on motif searches (Appel et al., 1994; Hansen et al., 1995; Hobohm and Sander, 1995) , contains the single potential sites for N-glycosylation (N at 257) and 0-glycosylation (T at 259). The C-terminal domain also contains the binding site for monoclonal antibody Al /118 as proteins produced in bacteria containing GPP130 amino acids between residues 278 and 433 reacted with Al/118, whereas those lacking this region did not. Because this antibody binds the lumenal domain of GPP130 and because GPP130 was found to be glycosylated and was protected from protease digestion by the Golgi membrane, we conclude that GPP130 is a type II integral membrane protein with a 12-residue cytoplasmic tail and a 665-residue lumenal domain. A serine at position 7 matches a protein kinase C consensus site and represents the sole potential cytoplasmic phosphorylation site. The lumenal domain contains multiple elements matching phosphorylation consensus sites, including 13 casein kinase II sites. Of unknown relevance is a match between the cytoplasmic N-terminal tail of GPP130 (amino acids 2-7) and the consensus sequence for myristylation (Hobohm and Sander, 1995) .
Comparison searches with sequences in the data banks did not reveal obvious GPP130 homologues. However, a long alignment was found between GPP130 and trichohyalin, a cytoplasmic calcium-binding protein predicted to form an elongated flexible rod that participates in keratin intermediate filament assembly (Lee et al., 1993) . Human trichohyalin is 28% identical and 50% similar in a stretch encompassing 95% of GPP130. The region of trichohyalin that aligns with GPP130 is largely composed of a variable length peptide repeat rich in glutamic acid and glutamine. Glutamic acid (19%) and glutamine (13%) are the most abundant amino acids in GPP130, and GPP130 does not contain a substantial repeating element. Nevertheless, the alignment between GPP130 and trichohyalin may reflect a structural similarity, because long alignments above 25% identity were also found between GPP130 and other filamentous proteins, including neurofilament subunit NF-180, involucrin, and myosin heavy chain. Interestingly, analysis of the GPP130 sequence with the COILS program (Lupas et al., 1991) indicated that GPP130 contains large noncontiguous regions predicted to participate in coiled-coil dimer formation ( Figure 6B) . A putative leucine zipper is also present (amino acids 114-135). Thus, the analysis indicates that the GPP130 protein sequence has not been previously identified in any organism and that GPP130 may form a flexible dimeric rod-shaped structure in the Golgi lumen. However, a few percent of the transfected CHO cells exhibited strong staining and a distinct and unexpected pattern, typified by a marked accumulation of punctate staining in a perinuclear position and distributed punctate staining in the cell periphery. To further investigate this pattern, we examined transfected COS-7 cells, which produce high levels of expressed protein because of their capacity to replicate the expression vector. Perinuclear and peripheral GPP130-positive vesicles were prominent in transfected COS-7 cells 2-3 d after transfection (Figure 8 , A, C, and E). This GPP130 overexpression pattern was not restricted to transiently transfected CHO or COS cells because a stably transfected HeLa cell line expressing GPP130 under the control of an inducible promoter (Gossen and Bujard, 1992 ) also showed a punctate GPP130 pattern after induction. Double-label immunofluorescence microscopy of COS-7 cells was used to better understand the abundant overexpression pattern. The overexpressed GPP130 only partially overlapped with the giantin pattern in the same cells (Figure 8, A and B) . Many GPP130-positive punctate structures, particularly those in the cell periphery, were devoid of giantin immunoreactivity but did partially colocalize with endosomal vesicles marked by mannose-6-phosphate receptor staining (Figure 8, C and D) or by uptake of fluorescent dextran (Figure 8, E and F) . To confirm that transfected cells accumulated GPP130 in endocytotic vesicles, we allowed the cells to endocytose Al / 118 or control antibodies. After 3 h of antibody uptake, prominent Al/ 118 accumulation in peripheral vesicles was found in transfected cells ( Figure 8G ) but not in nontransfected cells (Figure 8H) . The control anti-giantin antibody was not detectably endocytosed by either transfected or nontransfected cells. On the basis of these observations, we conclude that abundant overexpression of GPP130 led to partial mislocalization of GPP130 to endocytotic vesicles. Because previous reports have indicated that overexpression of type II Golgi proteins resulted in mislocalization to the ER rather than to post-Golgi compartments, we performed control transfections with human galactosyltransferase. In parallel transfections of COS-7 with either GPP130 or galactosyltransferase cloned in the same expression vector, we observed dramatically different patterns in cells expressing high levels of the transfected proteins. As previously reported, abundant overexpression of galactosyltransferase yielded prominent ER staining, whereas the punctate GPP130 pattern was completely distinct from an ER network pattern. Interestingly, overexpression of GPP130 appeared to convert the giantin pattern from the typical perinuclear ribbon into a perinuclear punctate pattern (Figure 8B ). This effect appeared to be specific to GPP130 overexpression as cells overexpressing galactosyltransferase did not exhibit an altered giantin pattern. A reduction in giantin staining intensity was also observed in GPP130 overexpressors, but giantin abundance, as determined by immunoblotting, was not significantly reduced. This suggests that giantin was diluted in the membrane of overexpressors. Electron microscopy was used to examine the basis of the staining change in GPP130-overexpressing cells. Cells overexpressing GPP130 ( Figure 9B ) were readily distinguished from nontransfected cells ( Figure 9A) (Yuan et al., 1987) . To test whether GPP130 is related to GIMPc, we obtained a rabbit antibody raised against GIMPc purified from rat (kindly contributed by Dr. I. Sandoval, Universidad Autonoma de Madrid, Madrid, Spain). This antibody and the A1/118 anti-GPP130 antibody were used in immunoblot analyses to examine extracts from control and GPP130-transfected HeLa cells, as well as extracts from control bacteria and bacteria producing a glutathione S-transferase (GST)-GPP130 fusion protein (Figure 10 ). Both cell types strongly overproduced their respective GPP130 constructs (lanes 2 and 6), and these proteins were specifically recognized by the antiGIMPc antibody (lanes 4 and 8). Significant degradation was also apparent, particularly in the bacterial extracts, and many of these degraded forms were detected by both antibodies. Longer exposures indicated that the anti-GIMPc antibody also detected a band in nontransfected HeLa cells that comigrated with endogenous or overexpressed GPP130. The purified GST-GPP130 fusion protein was also strongly reactive with both antibodies. On the basis of their antibody cross-reactivity, their similar biochemical characteristics, and their similar cellular localization, we conclude that GIMPc and GPP130 are homologous proteins. The phosphorylation of GPP130/GIMPc is on serine and is likely to be lumenal because it resists digestion in a protease protection assay (Yuan et al., 1987) . However, GIMPc phosphorylation was stimulated by dibutyryl cAMP treatment (Yuan et al., 1987) , and the cytosolic face of Golgi membranes contains a highaffinity binding site for the regulatory subunit of cyclic AMP-dependent kinase (Rios et al., 1992) . Because the short cytoplasmic tail of GPP130/GIMPc contains a serine and could be protease-resistant, we are currently testing whether this serine is required for GPP130/GIMPc phosphorylation. On the other hand, a number of proteins are phosphorylated in lumenal compartments, and GPP130/GIMPc has several potential casein kinase II sites in its lumenal domain. One of these matches a consensus sequence (SXE) recognized by a Golgi-localized class of casein kinase (LasaBenito et al., 1996) . The identity and location of the kinase that phosphorylates GPP130/GIMPc remains to be determined.
Even though it resides in the early Golgi and has a 20-h half-life, GPP130/GIMPc is quantitatively modified by sialyltransferase, which is located in the transGolgi/trans-Golgi network (Yuan et al., 1987) . How does GPP130/GIMPc become sialylated? One possibility is that GPP130/GIMPc is modified by newly synthesized sialyltransferase that is transiting through the early Golgi. This explanation would be consistent with retention models for Golgi targeting, because GPP130/GIMPc would not have to leave the early Golgi to acquire late Golgi modifications. An alternative possibility is suggested by our finding that elevating the pH of lumenal compartments with chloroquine caused a redistribution of GPP130/GIMPc to peripheral dilated vesicles, which appear to be endosomes. These data indicate that retention of GPP130/ GIMPc in the early Golgi is weak or nonexistent. Thus, GPP130/GIMPc may continually leak out of the early Golgi into the late Golgi where it encounters sialyltransferase. The transmembrane domain of GPP130/ GIMPc is 20 residues, 5 residues longer than the average for Golgi-localized type II proteins (Bretscher and Munro, 1993) ; this difference might allow GPP130/GIMPc to escape retention in the early Golgi. If GPP130/GIMPc reaches the late Golgi, a retrieval mechanism must operate to return it to the early Golgi (Johnston et al., 1994; Hoe et al., 1995; Harris and Waters, 1996) . This retrieval mechanism appears to be saturable, because we found that overexpression of HeLa GPP 130 GNIMPc GPP130/GIMPc led to its mislocalization. In contrast, previously studied type II Golgi proteins are localized by a nonsaturable chloroquine-insensitive mechanism. Interestingly, mislocalized GPP130/GIMPc accumulated in endosomes rather than at the plasma membrane, suggesting that this protein contains targeting information that functions in the TGN/endosomal system. A great deal of descriptive information is available regarding the structure of the Golgi apparatus (Rambourg and Clermont, 1990) , but the proteins that establish and regulate Golgi structure have not been identified. The lumenal domain of GPP130/GIMPc contains features that point to a structural rather than enzymatic role. Our analysis revealed that GPP130/ GIMPc overexpression led to vesiculation and/or dilation of the Golgi. The mechanistic basis for this effect is unclear. GPP130/GIMPc overexpression was not accompanied by substantial defects in secretion. GPP130/GIMPc appears to be structurally similar to cytoskeletal proteins, possibly indicating a related function for GPP130/GIMPc in the Golgi lumen. Alternatively, the high concentration of acidic residues in the GPP130/GIMPc lumenal domain may mean that this protein functions in maintaining the ionic balance within the Golgi, perhaps by providing lowaffinity high-capacity calcium binding (Antebi and Fink, 1992; Scherer et al., 1996) . Further work should uncover the function of GPP130/GIMPc and shed light on the intriguing question of how proteins are localized to the Golgi.
